Other Blood Products
Components of the blood that cannot be assigned to one of the other above-mentioned groups of medicines.
| Name | Marketing Authorisation Holder | License Number | License Date | Further Information |
|---|---|---|---|---|
|
FEIBA NF 500 E |
Shire Deutschland GmbH |
PEI.H.03340.01.1 | 12.12.2005 | |
|
FEIBA NF 1000 E |
Shire Deutschland GmbH |
PEI.H.03340.02.1 | 12.12.2005 | |
Jetrea |
ThromboGenics NV, B-3001 Leuven |
EU/1/13/819 | 13.03.2013 | Rote-Hand-Brief: Jetrea - Ocriplasmin (21.08.2018) |
|
Normosang |
Recordati Rare Diseases |
PEI.H.03381.01.1 | 15.10.2006 | |
|
Ondexxya |
Portola Netherlands B.V. |
EU/1/18/1345 | 26.04.2019 | |
|
Prolastin (Alpha-1 Proteinaseinhibitor) |
Grifols Deutschland GmbH |
12944.01.00 | 14.12.1988 | |
|
Respreeza |
CSL Behring GmbH |
EU/1/15/1006 | 20.08.2015 |
Hints
Disclaimer
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 477 in BAnz AT 16.02.2021 B7.
Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 01.03.2021
